BRCA1 and ovarian carcinoma: In addition, a study examining the role of taxane monotherapy in germline BRCA1/2 mutation carriers with relapsed ovarian cancer found a significant survival benefit in patients with initially platinum-sensitive disease compared to those with platinum-resistant disease [29].